Novo Nordisk's Wegovy Pill: FDA Approval, Efficacy, and UK MHRA Regulatory Expansion
The commercial launch of Novo Nordisk's oral Wegovy (semaglutide) tablets has demonstrated unprecedented market adoption, establishing it as one of the fastest-growing pharmaceutical launches by volume in US history. As of June 7, 2026, the drug has crossed a major commercial milestone by surpassing three million prescriptions in the United States in just over five months since its January 5, 2026 launch.
The trajectory of Wegovy pill adoption has shown dramatic acceleration:
- First 1 Million Prescriptions: Reached in 12 weeks (late March 2026).
- Next 2 Million Prescriptions: Accumulated in just 10 weeks, representing a significant steepening of the adoption curve.
- Velocity: The milestone corresponds to approximately one prescription being filled every five seconds across the US.
Crucially for investors, the data shows that the oral formulation is not merely cannibalizing Novo's existing injectable business. Over 80% of the new Wegovy pill prescriptions are for patients who are entirely new to GLP-1 therapy1, indicating that the convenience of an oral tablet is substantially expanding the addressable market.
In parallel, Novo Nordisk has seen strong early uptake for its high-dose injectable option, Wegovy HD (7.2 mg), and is preparing for its first international launches of the Wegovy pill in the second half of 2026, following recent approval and launch in the United Arab Emirates.
-
An instance of Injected biological peptides cannot scale to meet mass metabolic demand. — Broad physical adoption of the oral tablet proves that needle-free convenience expands the addressable patient market. ↩︎